Battling polycythemia vera (PV)? It's a condition that can significantly impact your life, but a new treatment, rusfertide, is showing promising results in managing this disease. This weekly, self-injected peptide is making waves, and here's what you need to know.
Results from the phase 3 VERIFY study, presented at the American Society of Hematology (ASH) 2025 Annual Meeting, highlight rusfertide's effectiveness. Led by Dr. Andrew Kuykendall, the study revealed that rusfertide maintained controlled hematocrit levels and reduced the need for phlebotomy over 52 weeks.
What does this mean for patients? Of those initially on rusfertide, a remarkable 61.9% didn't require phlebotomy for the entire 52-week period. Even more impressive, among patients who switched from a placebo to rusfertide at 32 weeks, 77.9% avoided phlebotomy between weeks 40 and 52, a significant jump from the initial 32.9% during the first 32 weeks. The average hematocrit level remained below 43% in both groups.
Rusfertide works by mimicking the hormone hepcidin, which plays a crucial role in regulating iron in the body. Dr. Kuykendall emphasized that rusfertide can safely control blood counts, reducing the risk of cardiovascular events and improving disease-related symptoms.
But here's where it gets controversial... PV causes the overproduction of red blood cells, leading to symptoms like itching, night sweats, and fatigue. Traditionally, treatment involves therapeutic phlebotomy to reduce hematocrit levels. However, this can often lead to iron deficiency and frequent visits to healthcare facilities.
Dr. Kuykendall pointed out that maintaining a hematocrit level below 45% is linked to a lower risk of major cardiovascular events. Rusfertide appears to achieve this goal effectively, potentially reducing the need for frequent phlebotomies.
Let's dive into the specifics: The VERIFY trial's initial 32-week results showed that patients on rusfertide required an average of 0.5 phlebotomies compared to 1.8 for those on the placebo. A key secondary endpoint revealed that 62.6% of patients taking rusfertide maintained a hematocrit below 45%, compared to only 14.4% in the placebo group.
The new analysis revealed that from weeks 32 to 50, the median time to first phlebotomy was not reached in either the initial rusfertide or placebo groups.
Improvements in fatigue and other symptoms were sustained in the rusfertide group. The most common side effects included injection-site reactions (47.4%), anemia (25.6%), and fatigue (19.6%), with most being mild to moderate.
And this is the part most people miss... Serious adverse events occurred in 8.1% of rusfertide-treated patients. Non-PV related malignancies were observed in 2.1% and 5.5% of patients in the rusfertide and placebo groups, respectively, from weeks 0 to 32 weeks and in 2.2% of all patients from weeks 32 to 52. Dr. Kuykendall highlighted the importance of monitoring for non-melanoma skin cancers, which can be exacerbated by some PV therapies.
Injection-site reactions tended to improve over time. Two patients in the rusfertide group experienced thrombotic events.
Experts not involved in the study have also weighed in. Dr. Gabriela S. Hobbs of Harvard Medical School praised the study's results, noting that patients switching to rusfertide from the placebo arm saw similar improvements to those who started on the drug. She emphasized that the extension data confirms the durability of the responses and the absence of new safety concerns.
In a nutshell: Rusfertide offers a promising alternative that could eliminate the need for therapeutic phlebotomy, which is a significant burden for PV patients.
What's next? The VERIFY study is ongoing, and FDA approval is being pursued.
Controversy & Comment Hooks: What are your thoughts on this new approach to managing PV? Do you think the potential benefits outweigh the risks? Share your opinions in the comments below!
